These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 23425264)

  • 21. Biosimilars.
    Malozowski S
    Arq Bras Endocrinol Metabol; 2011 Nov; 55(8):669. PubMed ID: 22218453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Europe offers example for approving biosimilars.
    Carroll J
    Manag Care; 2013 Sep; 22(9):4-5. PubMed ID: 24167835
    [No Abstract]   [Full Text] [Related]  

  • 23. The preclinical development of biosimilars: introduction.
    Bui LA
    Drug Discov Today; 2015 May; 20 Suppl 1():1-2. PubMed ID: 25843638
    [No Abstract]   [Full Text] [Related]  

  • 24. 9th GCC closed forum: CAPA in regulated bioanalysis; method robustness, biosimilars, preclinical method validation, endogenous biomarkers, whole blood stability, regulatory audit experiences and electronic laboratory notebooks.
    Hayes R; LeLacheur R; Dumont I; Couerbe P; Safavi A; Islam R; Pattison C; Cape S; Rocci M; Briscoe C; Cojocaru L; Groeber E; Silvestro L; Bravo J; Shoup R; Verville M; Zimmer J; Caturla MC; Khadang A; Bourdage J; Hughes N; Fatmi S; Di Donato L; Sheldon C; Keyhani A; Satterwhite C; Yu M; Fiscella M; Hulse J; Lin ZJ; Garofolo W; Savoie N; Xiao YQ; Kurylak K; Harris S; Saxena M; Buonarati M; Lévesque A; Boudreau N; Lin J; Khan MU; Ray G; Liu Y; Xu A; Soni G; Ward I; Kingsley C; Ritzén H; Tabler E; Nicholson B; Bennett P; van de Merbel N; Karnik S; Bouhajib M; Wieling J; Mulvana D; Ingelse B; Allen M; Malone M; Fang X
    Bioanalysis; 2016 Mar; 8(6):487-95. PubMed ID: 26916197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comments on the FDA draft guidance on biosimilar products.
    Chow SC; Endrenyi L; Lachenbruch PA
    Stat Med; 2013 Feb; 32(3):364-9. PubMed ID: 22903309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Biosimilar drugs – just as good, and much cheaper].
    Goll GL
    Tidsskr Nor Laegeforen; 2019 Mar; 139(6):. PubMed ID: 30917643
    [No Abstract]   [Full Text] [Related]  

  • 27. Effective pharmaceutical regulation needs alignment with doctors.
    Ebbers HC; Pieters T; Leufkens HG; Schellekens H
    Drug Discov Today; 2012 Feb; 17(3-4):100-3. PubMed ID: 22001600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations.
    Chamberlain P
    Bioanalysis; 2013 Mar; 5(5):561-74. PubMed ID: 23425272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [What is exactly alike? High-performance analytics for development of biosimilars].
    Blüggel M
    Pharm Unserer Zeit; 2012 Nov; 41(6):468-73. PubMed ID: 23362550
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparability and biosimilarity: considerations for the healthcare provider.
    Lee JF; Litten JB; Grampp G
    Curr Med Res Opin; 2012 Jun; 28(6):1053-8. PubMed ID: 22519391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gel electrophoretic methods for the analysis of biosimilar pharmaceuticals using the example of recombinant erythropoietin.
    Reichel C; Thevis M
    Bioanalysis; 2013 Mar; 5(5):587-602. PubMed ID: 23425274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioanalytical inspections: organizational changes and regulatory perspectives.
    Haidar SH; Scheibner KA
    Bioanalysis; 2016 May; 8(10):999-1002. PubMed ID: 27079934
    [No Abstract]   [Full Text] [Related]  

  • 33. Biosimilar draft guidance issue by US FDA.
    Payne T
    Bioanalysis; 2012 Apr; 4(7):759. PubMed ID: 22512794
    [No Abstract]   [Full Text] [Related]  

  • 34. State laws on biosimilars may drive up plans' costs.
    Carroll J
    Manag Care; 2013 Apr; 22(4):8-9. PubMed ID: 23682380
    [No Abstract]   [Full Text] [Related]  

  • 35. Precision and robustness of 2D-NMR for structure assessment of filgrastim biosimilars.
    Ghasriani H; Hodgson DJ; Brinson RG; McEwen I; Buhse LF; Kozlowski S; Marino JP; Aubin Y; Keire DA
    Nat Biotechnol; 2016 Feb; 34(2):139-41. PubMed ID: 26849514
    [No Abstract]   [Full Text] [Related]  

  • 36. Assessing the bioequivalence of biosimilars The Retacrit case.
    Schellekens H
    Drug Discov Today; 2009 May; 14(9-10):495-9. PubMed ID: 19429509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An adapted F-test for homogeneity of variability in follow-on biological products.
    Yang J; Zhang N; Chow SC; Chi E
    Stat Med; 2013 Feb; 32(3):415-23. PubMed ID: 22933180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry.
    Beck A; Sanglier-Cianférani S; Van Dorsselaer A
    Anal Chem; 2012 Jun; 84(11):4637-46. PubMed ID: 22510259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimation and approximation approaches for biosimilar index based on reproducibility probability.
    Yang LY; Lai CH
    J Biopharm Stat; 2014; 24(6):1298-311. PubMed ID: 25033191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The regulatory framework of biosimilars in the European Union.
    Minghetti P; Rocco P; Cilurzo F; Vecchio LD; Locatelli F
    Drug Discov Today; 2012 Jan; 17(1-2):63-70. PubMed ID: 21856438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.